Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women

Menopause International

Volumn 13, Issue 3, 2007, Pages 124-131

  Mattsson, L A ^a   Skouby, S ^b   Rees, M ^c   Heikkinen, J ^d   Kudela, M ^e   Stadnicki Kolendo, A ^f   Mattila, L ^g   Salminen, K ^g   Vuorela, A ^g   Mustonen, M ^g  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d OULU DEACONESS INSTITUTE   (Finland)

^e UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^f NZOZ GCP Dobra Praktyka Lekarska ^*  (Poland)

^g ORION CORPORATION   (Finland)

Author keywords

CONTINUOUS COMBINED HRT; HORMONE REPLACEMENT THERAPY; HOT FLUSHES; MENOPAUSE; POSTMENOPAUSAL WOMEN

Indexed keywords

DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE;

AGED; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; POSTMENOPAUSE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME; WOMEN'S HEALTH; ADULT; BLEEDING; BREAST DISEASE; BREAST TENDERNESS; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM BIOPSY; FIBROADENOMA; GYNECOLOGICAL EXAMINATION; HORMONE SUBSTITUTION; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALAISE; MAMMOGRAPHY; MASTALGIA; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; SIDE EFFECT; SPOTTING; TREATMENT DURATION; UTERINE CERVIX CYTOLOGY; UTERUS MYOMA; VASOMOTOR DISORDER; WEIGHT GAIN;

AGED; AMENORRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PATIENT SATISFACTION; POSTMENOPAUSE; QUESTIONNAIRES; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 38449112497     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507781605596     Document Type: Article

References (35)

1. Stearns V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet 2002;360: 1851–61.
2. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978.
3. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006;54:3194–204.
4. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162:404–14.
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
7. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673–84.
8. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523–34.
9. Grady D. Postmenopausal hormones – therapy for symptoms only. N Engl J Med 2003;348:1835–67.
10. Herrington DM, Howard TD. From presumed benefit to potential harm – hormone therapy and heart disease. N Engl J Med 2003;349:519–21.
11. Bailar J. Hormone replacement therapy and cardiovascular disease. N Engl J Med 2003;349:521–2.
12. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998;97:979–86.
13. Nabulsi AA, Folsom AR, White A, et al. Association of hormonereplacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069–75.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13.
15. Stampfer MJ, Colditz, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756–62.
16. Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;(3): CD000402.
17. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999;130:897–904.
18. Figueras F, Castelo-Branco C, Pons F, et al. Effect of continuous and sequential oral estrogen–progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study. Eur J Obstet Gynecol Reprod Biol 2001;99:261–5.
19. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997;27:69–76.
20. Heikkinen JE, Vaheri RT, Ahomaki SM, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol 2000;182:560–7.
21. Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999;94:323–9.
22. Bruhat M, Vaheri R, Kainulainen P, et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Maturitas 2001;40:259–71.
23. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen–progestin regimens. Osteoporos Int 2000;11:929–37.
24. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004;10:95–102.
25. J Br Menopause Soc 2004;10:168.
26. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc 2005;11:145–51.
27. Kelly JP, Kaufman DW, Rosenberg L, et al. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005;14:837–42.
28. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products for the Treatment of Hormone Replacement Therapy (CHMP/EWP/021/97). London: European Medicines Agency, 1997.
29. Mattsson LA, Skouby SO, Heikkinen J, et al. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional- dose regimen. Climacteric 2004;7:59–69.
30. Pitkin J, Rees MC, Gray S, et al. Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy. J Br Menopause Soc 2005;11:152–6.
31. Erkkola R, Kumento U, Lehmuskoski S, et al. No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen– progestogen therapy after five years. J Br Menopause Soc 2004;10: 9–13.
32. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739–48.
33. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen– progestogen replacement therapy: follow up study. BMJ 2002; 325:239.
34. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001;54:435–40.
35. Bergeron C, Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone. Maturitas 2001;37:191–9.